Honghong Zhou

2002–2025 年に発表

別表記
HongHong Zhou
80
論文数
25,893
被引用数
41
h 指数
69
i10 指数

被引用数

Honghong Zhou の年別被引用数1969 年: 被引用 1 件1974 年: 被引用 1 件2001 年: 被引用 1 件2003 年: 被引用 1 件2004 年: 被引用 7 件2005 年: 被引用 15 件2006 年: 被引用 14 件2007 年: 被引用 14 件2008 年: 被引用 14 件2009 年: 被引用 16 件2010 年: 被引用 32 件2011 年: 被引用 27 件2012 年: 被引用 33 件2013 年: 被引用 22 件2014 年: 被引用 15 件2015 年: 被引用 72 件2016 年: 被引用 240 件2017 年: 被引用 259 件2018 年: 被引用 249 件2019 年: 被引用 622 件2020 年: 被引用 640 件2021 年: 被引用 2,533 件2022 年: 被引用 2,352 件2023 年: 被引用 1,084 件2024 年: 被引用 1,363 件2025 年: 被引用 643 件2026 年: 被引用 14 件1970〜1973 年は被引用が無いため表示していません1975〜2000 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,110 件、この内訳の 26.5%中国: 引用元論文 1,555 件、この内訳の 10%イギリス: 引用元論文 949 件、この内訳の 6.1%ドイツ: 引用元論文 711 件、この内訳の 4.6%イタリア: 引用元論文 697 件、この内訳の 4.5%カナダ: 引用元論文 562 件、この内訳の 3.6%フランス: 引用元論文 554 件、この内訳の 3.6%オーストラリア: 引用元論文 538 件、この内訳の 3.5%オランダ: 引用元論文 409 件、この内訳の 2.7%スペイン: 引用元論文 375 件、この内訳の 2.4%日本: 引用元論文 364 件、この内訳の 2.4%スイス: 引用元論文 312 件、この内訳の 2%
0%26.5%その他 28.1%

分野

  • Medicine70.8%
  • Biochemistry, Genetics and Molecular Biology16.6%
  • Immunology and Microbiology5.5%
  • Social Sciences1.9%
  • Mathematics1.1%
  • Engineering0.8%
  • その他3.3%

トピック

  • SARS-CoV-2 and COVID-19 Research13.9%
  • Cancer Immunotherapy and Biomarkers7.9%
  • COVID-19 Clinical Research Studies5.6%
  • Immunotherapy and Immune Responses5.4%
  • Vaccine Coverage and Hesitancy3.4%
  • CAR-T cell therapy research3.3%
  • その他60.5%

共著者

全論文

検索で開く
  1. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brett Leav, Weiping Deng, Honghong Zhou, Shu Han, Melanie Ivarsson, Jacqueline Miller, Tal Zaks - New England Journal of Medicine 2020 被引用: 10,720

  2. Pembrolizumab versus Ipilimumab in Advanced Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 5,847

  3. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Colleen F. Kelley, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Lindsay N. Carpp, Rolando Pajón, Dean Follmann, Rubén O. Donis, Richard A. Koup, Immune Assays Team§, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team§, United States Government (USG)/CoVPN Biostatistics Team§ - Science 2022 被引用: 1,211

  4. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shu Han, Brett Leav, Deb Manzo, Rolando Pajón, F. Schödel, Joanne E. Tomassini, Honghong Zhou, Jacqueline M. Miller - New England Journal of Medicine 2021 被引用: 658

  5. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 1,239

  6. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

    著者: , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 371

  7. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kelly Hautzinger, Bethany Girard, Karen Slobod, Roderick McPhee, Rolando Pajón, Anne Aunins, Rituparna Das, Jacqueline M. Miller, Sabine Schnyder Ghamloush - New England Journal of Medicine 2022 被引用: 141

  8. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 175

  9. piRBase: integrating piRNA annotation in all aspects

    著者: , , , , , , , , , , , - Nucleic Acids Research, Nucleic Acids Res. 2021 被引用: 103

  10. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alicia Widge, Nancy J. Sullivan, Paul C. Roberts, John H. Beigel, Bette Korber, Lindsey R. Baden, Hana El Sahly, Spyros Chalkias, Honghong Zhou, Jing Feng, Bethany Girard, Rituparna Das, Anne Aunins, Darin K. Edwards, Mehul S. Suthar, John R. Mascola, David C. Montefiori - New England Journal of Medicine 2022 被引用: 391

  11. SmProt: A Reliable Repository with Comprehensive Annotation of Small Proteins Identified from Ribosome Profiling

    著者: , , , , , , , , , , , , - Genomics Proteomics & Bioinformatics, Genom. Proteom. Bioinform. 2021 被引用: 88

  12. NyuWa Genome resource: A deep whole-genome sequencing-based variation profile and reference panel for the Chinese population

    著者: , , , , , , , , , , , , - Cell Reports 2021 被引用: 132

  13. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

    著者: , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 144

  14. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

    著者: , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2023 被引用: 77

  15. A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 69

  16. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hana M. El Sahly, Lindsey R. Baden, Sharon E. Frey, Elissa Malkin, Stephen A. Spector, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Lindsay N. Carpp, Rolando Pajón, Dean Follmann, Rubén O. Donis, Richard A. Koup, Peter B. Gilbert, on behalf of the Immune Assays, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE), United States Government (USG)/CoVPN Biostatistics Teams - Science Translational Medicine 2023 被引用: 48

  17. Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Journal of Infectious Diseases 2024 被引用: 41

  18. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Xing Chen, Jing Feng, LaRee Tracy, Honghong Zhou, Jacqueline M. Miller, Rituparna Das, Claire Bethune, Marta Boffito, Duncan L. Browne, Marcin Bula, Fiona Burns, David Chadwick, Rebecca A. Clark, Catherine A. Cosgrove, Paul I. Dargan, Thomas C. Darton, C.J. Duncan, Stevan R. Emmett, Eva Galiza, James Galloway, Paul T. Heath, Lucy Jones, Philip A. Kalra, R.M. Kaminski, Rajeka Lazarus, Patrick Lillie, Patrick Moore, Ed Moran, Rhiannon Nally, Adrian Palfreeman, Alberto San Francisco Ramos, Tommy Rampling, Anju Sahdev, Dinesh Saralaya, Ray Sheridan, Roy L. Soiza - The Lancet Infectious Diseases 2023 被引用: 53

  19. A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults

    著者: , , , , , , , , - Vaccine 2023 被引用: 40

  20. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

    著者: , , , , , , , , , , , , - Annals of Internal Medicine 2022 被引用: 138

  21. 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

    著者: , , , , , , , , , , , , , , , - Late-breaking abstracts 2020 被引用: 54

  22. Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies

    著者: , , , , , , , , , , , , , , , , , , - Cancer Research 2020 被引用: 41

  23. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 被引用: 44

  24. OTUB1 promotes esophageal squamous cell carcinoma metastasis through modulating Snail stability

    著者: , , , , , , - Oncogene 2018 被引用: 95